Dana-Farber and UC San Diego oncologists preview ASCO 2026's top themes — pan-RAS inhibition, adjuvant selpercatinib, and perioperative therapy in high-risk prostate cancer.
Back
Practice-Changing Themes From ASCO 2026
Dr. Zunairah Shah of Roswell Park Comprehensive Cancer Center moderated a discussion with Dr. Jia Luo of Dana-Farber Cancer Institute and Dr. Yu-Wei Chen of UC San Diego to break down ASCO 2026's most practice-changing data — from perioperative prostate cancer results to a pan-RAS inhibitor breakthrough in pancreatic cancer.
Practice-Changing Themes From ASCO 2026
Episodes
All
All
Experts explain how toxicity and treatment setting, not just efficacy, drive sequencing decisions in PROTEUS's apalutamide regimen and the adjuvant selpercatinib lung cancer trial.
Oncologists discuss testing-access gaps — lung cancer tissue biopsy bottlenecks and prostate cancer genomic testing — that limit which patients benefit from ASCO 2026's precision oncology advances.
From HIF-2α inhibitors in kidney cancer to the pan-RAS breakthrough in pancreatic cancer, two oncologists highlight the pipeline drugs and trials set to reshape oncology's next wave.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
The OncFive: Top Oncology Articles for the Week of 10/4/2026
3
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
4
Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer
5